Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2022 call → NOWe need to determine if management conveys that successive engagements of the same kind are coming in at progressively larger size. The question asks: does management describe that the company's successive engagements of the same kind are coming in at progressively larger size? That is, does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago? We need to look for evidence in the transcript. The transcript includes statements from Ric Fulop and James Haley. We need to see if they mention that the size of individual deals or engagements is escalating. Let's scan the transcript for relevant statements. Ric Fulop says: "We continue to see momentum in blue chip customer adoption of our AM 2.0 solutions across industries, and we've included some examples of production and use cases in the appendix of this presentation. Please check them out. Detailing a few specific customer examples. BMW is using our solutions for critical components in their M Series automotive engines and is in process of expanding capacity to support a larger percentage of their vehicles. Tesla suppliers are extensively using our technology to validate designs before cutting tools for their Giga casting process. General Motors prints molds for casting for key vehicle components using our solutions. And Grainger World uses our printers to produce Formula 1 and Moto GP engine blocks. In Aerospace, we have a growing business with leading companies such as Precision Castparts, Consolidated Precision Products, Honeywell, Lockheed Martin, Rolls-Royce, Northrop Grumman, all of which are increasingly using our AM 2.0 solutions to make end-use parts in series production. Companies like Collins Aerospace are now using our technology for a variety of parts in aircraft interiors. Other major OEMs include Caterpillar printing molds for valve bodies, cylinder heads and critical spare parts; Mercury Marine, which uses our technology to manufacture their newest marine engines; and Emerson, which uses our printers to guarantee cross-border quality across plants around the world. Our defense business is also growing rapidly.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.